• SB 431542: From ALK5 Biology to Translation

  2026-08-24

  A translational framework for using SB 431542 to connect ALK5-dependent Smad2 signaling with macrophage–neuron injury, glioma biology, and immune-response studies—while keeping mechanistic inference, model maturity, and research-use limitations in view.

• Ziprasidone, GOT1, and PDAC Metabolic Reprogramming

  2026-08-24

  A 2022 Journal of Molecular Medicine study identifies ziprasidone as a non-competitive inhibitor of GOT1, linking pharmacological target engagement to glutamine-metabolism disruption in pancreatic ductal adenocarcinoma. Its integrated enzyme, cellular, metabolomic, and xenograft experiments provide a mechanistic framework for evaluating GOT1 as a vulnerability in PDAC, while also defining important limits for translation.

• JNJ-26481585 (Quisinostat) Assay Guide

  2026-08-23

  A scenario-based guide to using JNJ-26481585 (Quisinostat), SKU A4090, in cell viability, proliferation, apoptosis, and mechanistic assays. It connects HDAC inhibition, dose selection, formulation control, and TRIM21-associated drug resistance to practical laboratory decisions.

• Fluo-4 AM Calcium Assay Kit for Scaffold Studies

  2026-08-22

  Use live-cell calcium dynamics to connect electrospun scaffold fiber density with annulus fibrosus cell behavior. This workflow shows how the Fluo-4 AM Calcium Assay Kit can complement endpoint matrix analysis, support mechanotransduction studies, and scale toward receptor-focused screening.

• Chloroquine Diphosphate: From Flux to Translation

  2026-08-21

  Chloroquine Diphosphate is more than an autophagy reagent: it is a strategic perturbation tool for separating autophagosome formation, lysosomal clearance, cell-cycle control, and innate immune signaling. This article connects cancer-model applications with the HBsAg–TBK1 findings reported in Cell Death and Disease and outlines a more rigorous path from assay readouts to translational decisions.

• Mubritinib (TAK 165): Target-to-Assay Guide

  2026-08-20

  Mubritinib (TAK 165) is more than a historical HER2 inhibitor: it is a mechanistic probe of mitochondrial complex I, OXPHOS dependence, and protein binding. This guide translates its HSA interaction data into more interpretable AML, PEL, and cancer biology assays.

• UK-5099 for Whole-Blood Immunometabolism

  2026-08-20

  UK-5099, also known as PF-1005023, lets researchers test how mitochondrial pyruvate entry shapes cytokine responses without broadly removing extracellular glucose. This practical guide connects standardized whole-blood stimulation with mitochondrial respiration, insulinoma-cell assays, and glucose homeostasis studies while emphasizing controls, dose design, and troubleshooting.

• Canagliflozin and Mitochondria in Diabetic Kidney Cells

  2026-08-19

  Trentin-Sonoda and colleagues show that Canagliflozin improves mitochondrial network architecture and bioenergetic performance in proximal tubular cells from hypertensive–diabetic mice. The sex-dependent findings extend SGLT2 inhibitor research beyond glucose lowering and provide a mechanistic framework for studying renal protection in diabetic kidney disease.

• Elobixibat Hydrate: From IBAT to Translational Insight

  2026-08-19

  Elobixibat hydrate offers a compelling model of compartment-focused pharmacology: local ileal bile acid transporter inhibition can reshape colonic signaling, motility, and metabolic readouts without requiring high systemic exposure. This thought-leadership article connects IBAT biology with peristaltic-reflex research and provides a practical framework for translational validation.

• Sulfo-Cy3 azide for Neurodevelopmental Mapping

  2026-08-18

  Sulfo-Cy3 azide combines aqueous compatibility with bright orange-red fluorescence for labeling alkyne-bearing biomolecules, including oligonucleotides and potential EdU-based birthdating assays. This guide translates a rat claustrum development study into practical Click Chemistry fluorescent labeling, imaging, and troubleshooting workflows.

• Berberine Hydrochloride: A Causal Assay Map

  2026-08-18

  Berberine hydrochloride connects AMPK-centered metabolism with microbiome, tuft-cell, and osteoimmune biology. This article presents a causal assay framework for separating direct cellular effects from gut-mediated mechanisms in metabolic and bone research.

• UK-5099: A Mechanistic Lens on Immunometabolism

  2026-08-17

  UK-5099 (PF-1005023) is a mitochondrial pyruvate carrier inhibitor for connecting substrate transport with cellular phenotype. This article presents a decision framework for applying it across mitochondrial metabolism research, immune assays, and glucose-homeostasis studies without confusing transport blockade with global glycolytic inhibition.

• Fludarabine Workflows for Oncology Research

  2026-08-17

  Fludarabine provides a practical way to connect DNA replication stress with cell-cycle and apoptosis readouts in leukemia and multiple myeloma models. This guide covers formulation, dose-response design, mechanistic validation, genotype-aware assay planning, and troubleshooting for reproducible bench studies.

• HBTU for Precision Peptide Synthesis

  2026-08-16

  HBTU streamlines carboxylic acid activation for rapid, high-yield peptide bond formation in solid phase and solution workflows. Its practical value is especially clear when building enzyme-responsive peptide amphiphiles, where sequence fidelity, low racemization risk, and reproducible coupling directly influence downstream self-assembly assays.

• ML216 BLM Helicase Inhibitor Workflow Guide

  2026-08-15

  ML216 enables mechanism-focused interrogation of BLM-dependent DNA repair, from helicase assays and sister chromatid exchange to cell proliferation and chemotherapy-sensitization studies. This workflow emphasizes target controls, solvent discipline, and careful interpretation when extending BLM findings to WRN- or MSI-driven cancer models.

8358 records 1/558 page Next 12345 下5页 Last page